[Based on Japanese GAAP]
Operating Results
Overview of Operating Results
-
Net sales
56,607 million yen
YOY -
-
Operating profit
4,795 million yen
YOY -
-
Ordinary profit
4,880 million yen
YOY -
-
Profit attributable to owners of parent
4,290 million yen
YOY -
-
Earnings per share
151.22 yen
YOY 57.9 %
The Group’s net sales in the consolidated fiscal year under review were 56,607 million yen. Cost of sales was 30,255 million yen and selling, general and administrative expenses were 21,556 million yen, resulting in operating profit of 4,795 million yen. Ordinary profit was 4,880 million yen, after recording 379 million yen in non-operating income and 294 million yen in non-operating expenses. As a result of factors including the recording of 9,425 million yen in gain on sale of non-current assets through the sale of land and buildings owned by the consolidated subsidiary ASKA Pharmaceutical Co., Ltd., 9,683 million yen was recorded in extraordinary income. On the other hand, 8,400 million yen was recorded in extraordinary losses due to factors including the recording of 1,151 million yen in loss on valuation of investment securities, in addition to 6,891 million yen in extraordinary losses resulting from causes such as impairment of intangible assets due to suspension of development of CDB-2914 (Ulipristal) applied for by ASKA Pharmaceutical Co., Ltd. As a result of the above factors, profit attributable to owners of parent was 4,290 million yen.
Segment
Net sales
(Millions of yen)
| Segment name | 1Q | 2Q | 3Q | Full year |
|---|---|---|---|---|
| Pharmaceutical business | 12,840 | 25,619 | 39,685 | 50,791 |
| Animal health business | 1,351 | - | - | - |
| Others | 30 | 2,857 | 4,494 | 5,816 |
(i) Pharmaceutical business
Despite the impact of developments such as the first intermediate-year revision of NHI drug prices implemented in April 2021 and progress of measures to keep down medical care costs, the pharmaceutical drugs business showed favorable performance overall, due to factors such as growth in obstetrics and gynecology products, which are a major product line.
A look at results by product shows considerable growth in the obstetrics and gynecology area, to 7,334 million yen for the GnRH antagonist RELUMINA and 3,463 million yen for the dysmenorrhea agent FREWELL. In the internal medicine area, in addition to increases of 7,499 million yen for the thyroid hormone THYRADIN and 4,854 million yen for the poorly absorbable rifamycin antimicrobial agent RIFXIMA, growth in alternative demand spurred by problems in competitors’ supplies led to results of 12,394 million yen for the authorized generic CANDESARTAN and 5,183 million yen for the LH RH derivative microcapsule sustained-release formulation LEUPRORELIN.
As a result of the above factors, net sales were 50,791 million yen in this segment, and segment income was 5,088 million yen.
(ii) Others
Sales results for other businesses, which include animal health drugs, clinical testing, and medical devices, were favorable, centered on drugs for livestock and companion animals and feed additives in the animal health drugs business.
As a result of the above factors, net sales were 5,816 million yen in this segment, and segment income was 360 million yen.
Financial Position
Overview of Financial Position Summary
-
Total assets
83,297 million yen
Change from end of previous fiscal year 0.8%
-
Net assets
48,892 million yen
Change from end of previous fiscal year 9.8%
-
Equity ratio
58.7 %
Change from end of previous fiscal year 4.8point
Overview of Financial Position
(Assets)
Total assets at the end of the consolidated fiscal year under review stood at 83,297 million yen, comprising primarily 49,557 million yen in current assets, including 12,103 million yen in cash and deposits, 14,482 million yen in accounts receivable - trade, and 10,016 million yen in merchandise and finished goods, and 33,739 million yen in non-current assets, including 10,936 million yen in property, plant and equipment and 12,223 million yen in investment securities.
(Liabilities)
Total liabilities at the end of the consolidated fiscal year under review stood at 34,404 million yen, comprising primarily 16,011 million yen in current liabilities, including 3,118 million yen in notes and accounts payable - trade, 3,723 million yen in electronically recorded obligations, and 4,867 million yen in accounts payable - other, and 18,393 million yen in non-current liabilities, including 12,323 million yen in long-term borrowings and 5,730 million yen in retirement benefit liability.
(Net assets)
Total liabilities at the end of the consolidated fiscal year under review stood at 48,892 million yen, comprising primarily 45,419 million yen in shareholders’ equity, including 45,833 million yen in retained earnings, and 3,473 million yen in accumulated other comprehensive income, including 3,231 million yen in valuation difference on available-for-sale securities.
The resulting equity ratio was 58.7%.
Cash Flow Summary
-
Cash flows from operating activities
2,842 million yen
-
Cash flows from investing activities
6,743 million yen
-
Cash flows from financing activities
(2,996) million yen
-
Cash and cash equivalents at end of period
17,103 million yen
Overview of Cash Flow Position
The balance of cash and cash equivalents at the end of the current consolidated fiscal year (“funds” hereinafter) stood at 17,103 million yen.
The standing of each type of cash flow for the current fiscal year, and major contributing factors of each, are summarized below.
(Cash flows from operating activities)
Net cash provided by operating activities was 2,842 million yen, due mainly to profit before income taxes, impairment, and depreciation, which more than offset proceeds from sale of property, plant and equipment.
(Cash flows from investing activities)
Net cash provided by investing activities was 6,743 million yen, due mainly to sale of property, plant and equipment.
(Cash flows from financing activities)
Net cash used in financing activities was 2,996 million yen, due mainly to repayments of long-term borrowings.